Format

Send to

Choose Destination
Leukemia. 2019 Feb 18. doi: 10.1038/s41375-019-0418-8. [Epub ahead of print]

CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity.

Author information

1
Josep Carreras Leukemia Research Institute and Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain. cbueno@carrerasresearch.org.
2
Josep Carreras Leukemia Research Institute and Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
3
Pompeu Fabra University, Barcelona, Spain.
4
Instituto de Biomedicina y Biotecnología de Cantabria (CSIC-UC-Sodercan), Departamento de Biología Molecular, Universidad de Cantabria, Santander, Spain.
5
Hematology Department, Hospital Clínico de Barcelona, Barcelona, Spain.
6
Instituciò Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
7
Josep Carreras Leukemia Research Institute and Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain. pmenendez@carrerasresearch.org.
8
Instituciò Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. pmenendez@carrerasresearch.org.
9
Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), ISCIII, Barcelona, Spain. pmenendez@carrerasresearch.org.
PMID:
30778134
DOI:
10.1038/s41375-019-0418-8

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center